FDA Grants Breakthrough Device Designation to Beyond Air’s LungFit GO for NTM-PD Treatment
Event summary
- Beyond Air’s LungFit GO received FDA Breakthrough Device Designation for treating nontuberculous mycobacterial pulmonary disease (NTM-PD) on August 31, 2026.
- Pilot study results showed high treatment compliance, favorable safety profile, and signs of improvement in quality-of-life domains for NTM-PD patients.
- LungFit GO is a portable device that generates nitric oxide from ambient air, enabling home-based treatment for chronic pulmonary diseases.
- Beyond Air plans to leverage the FDA’s Breakthrough Devices Program to streamline clinical development and regulatory review for LungFit GO.
The big picture
Beyond Air’s Breakthrough Device Designation for LungFit GO highlights the growing interest in home-based treatments for chronic pulmonary diseases. The FDA’s designation underscores the significant unmet need in NTM-PD, a rare and serious condition with limited treatment options. This strategic move positions Beyond Air to potentially expand its nitric oxide platform beyond hospital settings, tapping into the broader trend of decentralized healthcare delivery.
What we're watching
- Regulatory Pathway
- How the Breakthrough Device Designation will accelerate the clinical development and regulatory review process for LungFit GO.
- Commercial Strategy
- Whether Beyond Air will prioritize LungFit GO’s development alongside its existing commercial business.
- Clinical Validation
- The pace at which Beyond Air can design and initiate a future pivotal clinical study for LungFit GO in NTM-PD.